KALA
Income statement / Annual
Last year (2023), Kala Pharmaceuticals, Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2023, Kala Pharmaceuticals, Inc.'s net income was -$42.20 M.
See Kala Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00
|
$3.89 M
|
$11.24 M
|
$6.36 M
|
$6.07 M
|
$0.00
|
$0.00
|
$0.00
|
$45,000.00
|
| Cost of Revenue |
$303,000.00 |
$2.56 M |
$4.10 M |
$3.17 M |
$2.01 M |
$955,000.00 |
$643,000.00 |
$297,000.00 |
$0.00 |
| Gross Profit |
-$303,000.00 |
$1.33 M |
$7.14 M |
$3.19 M |
$4.07 M |
-$955,000.00 |
-$643,000.00 |
-$297,000.00 |
$45,000.00 |
| Gross Profit Ratio |
0 |
0.34 |
0.64 |
0.5 |
0.67 |
0 |
0 |
0 |
1 |
| Research and Development
Expenses |
$18.59 M
|
$17.65 M
|
$11.52 M
|
$18.35 M
|
$27.28 M
|
$29.29 M
|
$29.01 M
|
$25.03 M
|
$11.38 M
|
| General & Administrative
Expenses |
$0.00
|
$65.04 M
|
$105.06 M
|
$81.07 M
|
$65.02 M
|
$35.43 M
|
$10.87 M
|
$7.64 M
|
$4.61 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$20.26 M
|
$65.04 M
|
$105.06 M
|
$81.07 M
|
$65.02 M
|
$35.43 M
|
$10.87 M
|
$7.64 M
|
$4.61 M
|
| Other Expenses |
$0.00 |
-$926,000.00 |
$1.31 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$39.15 M |
$82.69 M |
$116.58 M |
$99.42 M |
$92.29 M |
$64.72 M |
$39.88 M |
$32.67 M |
$15.99 M |
| Cost And Expenses |
$39.15 M |
$85.25 M |
$120.67 M |
$102.59 M |
$94.30 M |
$64.72 M |
$39.88 M |
$32.67 M |
$15.99 M |
| Interest Income |
$2.71 M |
$664,000.00 |
$104,000.00 |
$493,000.00 |
$2.36 M |
$1.69 M |
$527,000.00 |
$147,000.00 |
$0.00 |
| Interest Expense |
$5.81 M |
$7.27 M |
$8.38 M |
$8.59 M |
$8.48 M |
$3.31 M |
$1.02 M |
$767,000.00 |
$604,000.00 |
| Depreciation &
Amortization |
$303,000.00
|
$860,000.00
|
$2.27 M
|
$2.84 M
|
$2.62 M
|
$955,000.00
|
$643,000.00
|
$297,000.00
|
$330,000.00
|
| EBITDA |
-$36.08 M
|
-$36.70 M
|
-$131.96 M
|
-$92.90 M
|
-$83.25 M
|
-$62.47 M
|
-$40.55 M
|
-$32.10 M
|
-$15.75 M
|
| EBITDA Ratio |
0 |
-20.97 |
-9.52 |
-15.05 |
-14.14 |
0 |
0 |
0 |
-347.02 |
| Operating Income Ratio
|
0
|
-20.9
|
-9.74
|
-15.13
|
-14.52
|
0
|
0
|
0
|
-354.36
|
| Total Other
Income/Expenses Net |
-$3.05 M
|
$36.53 M
|
-$12.36 M
|
-$8.10 M
|
-$6.12 M
|
-$2.02 M
|
-$2.34 M
|
-$498,000.00
|
-$736,000.00
|
| Income Before Tax |
-$42.20 M |
-$44.82 M |
-$142.61 M |
-$104.33 M |
-$94.35 M |
-$66.74 M |
-$42.21 M |
-$33.17 M |
-$16.68 M |
| Income Before Tax Ratio
|
0
|
-11.52
|
-12.69
|
-16.4
|
-15.53
|
0
|
0
|
0
|
-370.71
|
| Income Tax Expense |
$0.00 |
-$44.60 M |
$9.69 M |
$7.68 M |
$7.64 M |
$1.30 M |
$732,000.00 |
$767,000.00 |
$604,000.00 |
| Net Income |
-$42.20 M |
-$223,000.00 |
-$152.30 M |
-$112.00 M |
-$101.98 M |
-$66.74 M |
-$42.21 M |
-$33.17 M |
-$16.68 M |
| Net Income Ratio |
0 |
-0.06 |
-13.55 |
-17.61 |
-16.79 |
0 |
0 |
0 |
-370.71 |
| EPS |
-17.35 |
-0.15 |
-116.79 |
-106.92 |
-149.06 |
-124.73 |
-305.74 |
-95.95 |
-48.26 |
| EPS Diluted |
-17.35 |
-0.15 |
-116.79 |
-106.92 |
-149.06 |
-124.73 |
-305.74 |
-95.95 |
-48.26 |
| Weighted Average Shares
Out |
$2.43 M
|
$1.52 M
|
$1.30 M
|
$1.05 M
|
$684,195.00
|
$535,078.00
|
$138,064.00
|
$345,667.00
|
$345,667.00
|
| Weighted Average Shares
Out Diluted |
$2.43 M
|
$1.52 M
|
$1.30 M
|
$1.05 M
|
$684,195.00
|
$535,078.00
|
$138,064.00
|
$345,667.00
|
$345,667.00
|
| Link |
|
|
|
|
|
|
|
|
|
